ProCE Banner Activity

BIC/FTC/TAF vs DTG + FTC/TDF in Persons With HIV and HBV Coinfection: The Story So Far

Clinical Thought
Read my take on an interesting clinical presentation from the recent AIDS 2022 Conference in Montreal evaluating TDF vs TAF in HIV/HBV coinfection.

Released: August 19, 2022

Expiration: August 18, 2023

No longer available for credit.

Share

Faculty

Jürgen K. Rockstroh

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner

Faculty Disclosure

Primary Author

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Jürgen K Rockstroh, MD: consultant/advisor/speaker: Abivax, Boehringer, Galapagos, Gilead, Janssen, Merck, Theratechnologies, Viiv.